Sware Raises $6M to Accelerate Life Sciences Innovation by Automating FDA-Mandated Software Validation [Yahoo! Finance]
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: Yahoo! Finance
BOSTON, June 06, 2024 BUSINESS WIRE Sware , provider of the most complete software validation solution for innovative life sciences companies, today announced that it raised $6 million in Series B funding, bringing its total raised since inception to $26 million. The round was led by First Analysis , which joins a syndicate of existing investors that includes LRVHealth New Stack Ventures and Insight Partners . The funding will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt, the unpaid cost of release, testing, GxP, and business requirements. As a result of the funding, Matt Nicklin, managing director at First Analysis, will join the company's board of directors. Innovation in the life sciences and biotechnology sectors continues to accele
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Needham & Company LLC from $12.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at HC Wainwright from $9.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- G1 Therapeutics discontinue COSELA in TNBC following Phase III flop [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $5.00.MarketBeat
- G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty [Seeking Alpha]Seeking Alpha
GTHX
Earnings
- 5/1/24 - Miss
GTHX
Sec Filings
- 6/24/24 - Form 8-K
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- GTHX's page on the SEC website